Deal includes rights to novel antibody for the treatment of inflammatory bowel disease.
Roche revealed in a company press release that it has entered into a definitive agreement to acquire Telavant Holdings, Inc. (Telavant), a Roivant company, owned by Roivant Sciences Ltd. and Pfizer Inc. With the deal including the development, manufacturing and commercialization rights in the US and Japan for Telavant’s RVT-3101, a novel TL1A directed antibody, Roche will pay a purchase price of $7.1 billion upfront and a near-term milestone payment of $150 million.
RVT-3101 is indicated for patients suffering from inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
“We strongly believe this novel TL1A directed antibody has the transformational potential to make a significant difference for patients living with inflammatory bowel disease and potentially other diseases,” said Thomas Schinecker, CEO Roche Group. “We are excited to add this promising new therapy in development to our portfolio and to make it available to patients as quickly as possible.”
Reference: [Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant. Roche. October 23, 2023. Accessed October 23, 2023. https://www.roche.com/media/releases/med-cor-2023-10-23
Source link
#Roche #Reaches #Definitive #Agreement #Acquire #Telavant
